Navigation Links
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Date:5/31/2008

.3 mg/m2 on days 1, 4, 8 and 11, and dexamethasone at 40 mg on days 1 through 4, 9 through 12, and 17 through 20 of a 28-day schedule. A total of four cycles was planned with a goal of proceeding on to stem cell transplant (SCT). Results were presented by Craig Reeder, M.D., Assistant Professor of Medicine, Mayo Clinic College of Medicine, and showed a CR rate of 46 percent prior to transplant, a CR rate of 72 percent post-transplant and an overall response rate (partial response or better) of 95 percent. Side effects included thrombocytopenia, neutropenia, hyperglycemia and peripheral neuropathy.

VELCADE, Pegylated-Lyposomal-Doxorubicin and dexamethasone (PAD or VcDD) as Induction Therapy Prior to Reduced Intensity ASCT Followed by Lenalidomide and Prednisone (LP) as Consolidation and Lenalidomide Alone as Maintenance (Abstract #8518)

This study of PAD (VcDD) was designed to evaluate the VELCADE combination as induction therapy prior to SCT in patients with newly diagnosed multiple myeloma. The results showed the status of 86 evaluable patients who received VELCADE at 1.3 mg/m2 on days 1, 4, 8, 11, DOXIL at 30 mg/m2 on day 4 and dexamethasone at 40 mg on days 1 through 4, 8 through 11, 15 through 18 for one cycle and on days 1 through 4 for cycles two through four. Cyclophosphamide at 3 g/m2 and G-CSF were used to harvest stem cells. Patients were then conditioned with two courses of melphalan at 100 mg/m2 (MEL100). Following SCT, patients received lenalidomide at 25 mg/day on days 1 through 21 plus prednisone at 50 mg every other day for four, 28-day LP cycles. This was followed by lenalidomide alone at 10 mg/day on days 1 through 21 every 28 days. Results were presented by Antonio Palumbo, M.D., Chief of the Myeloma Unit; Department of Hematology, University of Torino and showed 94 percent of patients achieved at least a partial response, including a CR rate of 21 percent after four cycles of VcDD. Post transplant, the CR rate increased to 59 percen
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015 BioElectronics Corporation (OTC ... Musculoskeletal Pain Therapy medical devices, announced today that ... ActiPatch 7-day trial device has been published in ... Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 ... submitted an assessment.  Chronic pain ...
(Date:8/4/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Animal Biotechnology - ... This report describes and evaluates animal ... pharmaceuticals as well as improvement in food production. ... application of biotechnology to manage genetic disorders and ...
(Date:8/4/2015)... Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX ),  a targeted oncology ... be presenting at the 2015 Wedbush PacGrow Healthcare Conference on ... PT) in New York . Charles ... will provide a corporate overview. A live audio ... page of Mirati,s corporate website at www.mirati.com . A ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3
... SPRING, Md., April 28, 2011 The U.S. ... acetate) in combination with prednisone (a steroid) to ... who have received prior docetaxel (chemotherapy). ... cancer, the male sex hormone testosterone stimulates prostate ...
... Sciences Inc. (PSI), a leading pharmaceutical CRO, and ... ethylene vinyl acetate (EVA) into pharmaceutical applications, are ... devices.  Building on years of collaboration, Particle Sciences ... provide Particle Sciences with preferred access to VitalDose™ ...
Cached Medicine Technology:FDA Approves Zytiga for Late-Stage Prostate Cancer 2FDA Approves Zytiga for Late-Stage Prostate Cancer 3Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations 2Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations 3
(Date:8/4/2015)... ... August 04, 2015 , ... PerceptiMed, ... Richard Carmona, M.D., M.P.H., FACS, to its Board of Directors effective August 1, ... lives," Dr. Carmona said. "I strongly believe in the mission of the company ...
(Date:8/4/2015)... ... August 04, 2015 , ... Seedstock’s ... for Nov. 3 – 4, 2015, at UC San Diego, will explore innovations ... improve food access, and manage resources efficiently against the dueling backdrop of a ...
(Date:8/4/2015)... Mount Horeb, WI (PRWEB) , ... August 04, 2015 , ... ... newly released video on the subject, Renew Man™ is standing up as a voice ... a 15-year veteran of the healthy aging industry with special experience and expertise in ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... They say ... better understand certain health conditions, pictures and medical art can be essential. StayWell, a ... providers. , Krames Patient Education solutions have been used by physicians and other ...
(Date:8/4/2015)... ... August 04, 2015 , ... Discovia, ... entities, today announced that John Munro, a 15-year veteran of the eDiscovery services ... Services Operations. , “I am thrilled to join Discovia at this important point ...
Breaking Medicine News(10 mins):Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3
... U.S. News & World Report has ranked,Cincinnati Children,s ... United States in general pediatrics in the 2008 edition ... is,the highest Cincinnati Children,s has ever received from U.S. ... we owe a great debt of thanks,to the thousands ...
... WASHINGTON, May 30 The National Alliance on,Mental ... for her,contributions to public education about mental illness ... 2008., NAMI executive director Mike Fitzpatrick made ... in which he discussed the premiere of,two ...
... May 30 The following is being issued,by the Federation ... physician scientists from 58 countries across the globe, What: ... When: Wednesday, June 4-Monday, June 9, Where: Boston Marriott ... accelerate science that improves patient care, Wednesday, June 4, ...
... is Dec. 31, but FDA urges asthma patients to ... (HealthDay News) -- Asthma inhalers that contain the drug ... harm the ozone layer. And these inhalers won,t be ... urging patients to switch to alternative inhalers now. , ...
... hardest hit ... areas of the country, WILMINGTON, ... homeless after Cyclone Nargis swept through Myanmar. Malteser,International has been providing ... of Labutta in the Irrawaddy Delta. Present in,Myanmar since 2001, Malteser ...
... Indiana experienced a 50 percent membership ... growth since 2007, ... this 14-year-old, not-for-profit,Indiana managed health care plan -- surpassing the 300,000 mark ... 2007, the,company has also grown its employee base by 182 percent -- ...
Cached Medicine News:Health News:U.S. News Ranks Cincinnati Children's Among Top Three U.S. Children's Hospitals 2Health News:U.S. News Ranks Cincinnati Children's Among Top Three U.S. Children's Hospitals 3Health News:NAMI Blog: PBS, MTV and Jane Pauley 2Health News:World-Renowned Scientists to Lead Immunology Course 2Health News:World-Renowned Scientists to Lead Immunology Course 3Health News:World-Renowned Scientists to Lead Immunology Course 4Health News:Ozone-Depleting Inhalers Being Phased Out 2Health News:Ozone-Depleting Inhalers Being Phased Out 3Health News:More Than 78,000 are Dead and Millions are Homeless After Cyclone Nargis Swept Through Myanmar 2Health News:MDwise Enrollment Exceeds 300,000 Members 2
...
ENDOlap™ suction and irrigation trumpet valves...
... Clinicians are demanding smaller, higher ... their clinical and operational challenges. The ... a powerful architecture for superb High ... mobility and ease-of-use; and a versatile ...
... The Dimension Vista 1500 integrated ... nephelometry, IMT (integrated multisensor technology) ... design will integrate analysis of ... drugs-of-abuse, therapeutic drugs, immunosuppressive drugs, ...
Medicine Products: